Cytokinetics, Incorporated
As of Oct 22, 2026, Cytokinetics is in Stage 4, the downtrend phase, now in its first week (since Oct 19, 2026). It closed at $62.33, 28.6% below its 52-week high and below its 200-day average, which is rising.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CYTK early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CYTK among Biotechnology156th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …156 | CYTK | Stage 4 · wk 1 | 61 | −5.3% |
Cytokinetics: quick answers
What stage is Cytokinetics in?
As of Oct 22, 2026, Cytokinetics (CYTK) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 19, 2026 and is in its first week there. What the four stages mean
Is Cytokinetics in an uptrend?
No. Cytokinetics is in a Stage 4 downtrend. It trades 11.1% below its 200-day average, which is rising.
How far is Cytokinetics from its 52-week high?
Cytokinetics closed at $62.33 on Oct 22, 2026, 28.6% below its 52-week high of $87.26. Its 52-week low is $54.76.
How has Cytokinetics performed over the past year?
As of Oct 22, 2026, Cytokinetics is up 7.9% over the past year and up 1.0% so far in 2026.
Which sector and industry is Cytokinetics in?
Cytokinetics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.